JAK2 V617F due to a novel TG → CT mutation at nucleotides 1848-1849: Diagnostic implication [18]

Leukemia

Volumn 21, Issue 6, 2007, Pages 1344-1346

  Wong, C L P ^a   Ma, E S K ^a   Wang, C L N ^a   Lam, H Y ^a   Ma, S Y ^b  

^a HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

^b St Paul's Hospital Hong Kong   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE; DNA; GUANINE; HYDROXYUREA; JANUS KINASE 2; THYMIDINE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; AGED; ALLELE; BLOOD EXAMINATION; BONE MARROW BIOPSY; CASE REPORT; DIAGNOSTIC VALUE; DNA EXTRACTION; FALSE NEGATIVE RESULT; FEMALE; HUMAN; HUMAN CELL; LETTER; MUTATIONAL ANALYSIS; MYELOFIBROSIS; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 34249747986     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404654     Document Type: Letter

References (8)

1. James C, Ugo V, Le Couédic J-P, Staerk J, Delhommeau F, Lacout C et al. A uique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005; 434: 1144-1148.
2. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
3. Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
4. Levine RL, Waddleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.
5. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2 V617F era. Hematology Am Soc Hematol Educ Program 2006, 240-245.
6. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459-468.
7. Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycyrthemia vera. Blood 2006; 108: 1865-1867.
8. McClure R, Mai M, Lasho T. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia 2006; 20: 168-171.